UCM-17017
UCM-17017 is a tetrasubstituted cyclohexene inhibitor that inhibits the activity of senescent cell SA-β-gal with an IC50 of 0.4 μM. UCM-17017 selectively reduces the viability of senescent cancer cells, and this effect is stronger than its impact on proliferating cells. UCM-17017 binds to human serum albumin with a KD of 230 μM. UCM-17017 reduces collagen deposition and decreases the expression of the inflammatory marker Ccl2 in a mouse model of pulmonary fibrosis. UCM-17017 can be used in studies related to senescence and pulmonary fibrosis.
For research use only. We do not sell to patients.
- Formula: C18H25FN2
- Molecular Weight:288.40
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
|
SA-β-gal 0.4 μM (IC50) |
UCM-17017 (compound 25) (1-10 μM; 48 h) inhibits SA-β-gal activity in senescent human lung fibroblasts (IMR-90), with an IC50 of 0.4 μM; at a concentration of 10 μM, it reduces the activity to 20%, and at 1 μM, it reduces the activity to 52%[1].
UCM-17017 (200 μM; 5 h) exhibits a permeability value of 8.4 × 10-6 cm/s in cell-free PAMPA assays[1].
UCM-17017 exhibits a half-life of over 48 h in human and mouse serum, demonstrating high serum stability[1].
UCM-17017 exhibits favorable metabolic stability in human and mouse liver microsomes, with half-lives of 5.0 h and 2.2 h, respectively[1].
UCM-17017 binds to human serum albumin with an occupancy rate of 72% and a KD of 230 μM[1].
UCM-17017 (100 μM; 30 min) does not inhibit hERG potassium channels, indicating a low risk of cardiotoxicity[1].
UCM-17017 (1-10 μM; 24-72 h) selectively reduces the viability of bleomycin (HY-108345)-induced senescent human lung adenocarcinoma (A549) cells, while exerting no such effect on proliferating A549 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:bleomycin-induced senescent human lung adenocarcinoma (A549) cells, proliferative A549 cells
-
Concentration:1 μM, 10 μM
-
Incubation Time:24 h, 48 h, 72 h
-
Result:Selectively reduced viability of senescent A549 cells compared to proliferative A549 cells.
Showed the greatest selectivity after 48-72 h post-treatment at both 1 μM and 10 μM.
Resulted in a viability ratio of proliferative to senescent A549 cells of approximately 1.3-fold.
| Species | Dose | Route | C0 | Vd | T1/2 | AUC | CL |
|---|---|---|---|---|---|---|---|
| Mice[1] | 40 mg/kg | i.p. | 111 μg/L | 365 L/kg | 1.87 h | 0.30 mg·h/L | 137 |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J (male, 10 weeks old, bleomycin-induced pulmonary fibrosis)[1]
-
Dosage:40 mg/kg
-
Administration:i.p.; daily; 7 days
-
Result:Significantly reduced collagen deposition in lung tissue to levels similar to the reference senolytic ABT-263.
Downregulated mRNA expression levels of the inflammation marker *Ccl2*.
Did not significantly reduce SA-β-gal activity.
Did not affect bleomycin-induced weight loss.
Did not induce structural damage, apoptosis, or toxicity in liver and kidney tissues.
Chemical Information
-
Molecular Weight 288.40
-
Formula C18H25FN2
-
SMILES
N[C@@H]1[C@@H](C2=CC=C(F)C=C2)[C@H](C)C=C(CNCC3CC3)C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
UCM-17017 Related Classifications
HY-187365 Related Classifications
Powered by Bioz